Wharton Business Group’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$413K Hold
1,172
0.02% 104
2025
Q4
$384K Hold
1,172
0.01% 107
2025
Q3
$331K Hold
1,172
0.01% 116
2025
Q2
$327K Sell
1,172
-4
-0.3% -$1.13K 0.01% 113
2025
Q1
$366K Hold
1,176
0.02% 108
2024
Q4
$306K Hold
1,176
0.01% 116
2024
Q3
$379K Hold
1,176
0.02% 110
2024
Q2
$367K Buy
1,176
+52
+5% +$15.3K 0.02% 106
2024
Q1
$320K Hold
1,124
0.02% 112
2023
Q4
$324K Hold
1,124
0.02% 109
2023
Q3
$302K Hold
1,124
0.02% 116
2023
Q2
$250K Buy
1,124
+1
+0.1% +$232 0.02% 120
2023
Q1
$271K Sell
1,123
-1
-0.1% -$245 0.02% 123
2022
Q4
$295K Sell
1,124
-204
-15% -$54.7K 0.02% 116
2022
Q3
$299K Hold
1,328
0.02% 111
2022
Q2
$323K Hold
1,328
0.02% 105
2022
Q1
$321K Hold
1,328
0.02% 108
2021
Q4
$299K Buy
+1,328
New +$280K 0.02% 109
2021
Q3
Sell
-1,312
Closed -$320K 69
2021
Q2
$320K Sell
1,312
-200
-13% -$49.2K 0.03% 99
2021
Q1
$376K Buy
1,512
+29
+2% +$6.92K 0.03% 92
2020
Q4
$341K Hold
1,483
0.03% 93
2020
Q3
$377K Hold
1,483
0.03% 80
2020
Q2
$350K Buy
1,483
+100
+7% +$22.8K 0.03% 83
2020
Q1
$280K Buy
1,383
+200
+17% +$43.7K 0.03% 81
2019
Q4
$285K Buy
+1,183
New +$261K 0.03% 99

Other funds holding AMGN

Wharton Business Group's AMGN Position: Q1 2026 in Review

Wharton Business Group held its Amgen (AMGN) position steady in Q1 2026 at 1,172 shares worth $413K. The position accounts for 0.02% of the portfolio, ranked #104.

Wharton Business Group first reported a position in AMGN in Q4 2019 and has held it in 25 quarters since. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Wharton Business Group held 1,172 shares of Amgen worth $413K as of Q1 2026.
  • Wharton Business Group left its Amgen share count unchanged in Q1 2026.
  • Amgen made up 0.02% of Wharton Business Group's portfolio in Q1 2026, its #104 holding.
  • Wharton Business Group first reported a position in Amgen in Q4 2019 and has held it in 25 quarters since.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Wharton Business Group's 13F filing for Q1 2026, filed 7 May 2026.